Monitor the stock's bid price closely ahead of the November 23, 2026 deadline. A reverse stock split announcement could provide a temporary boost, but failure to maintain compliance would lead to delisting and potential loss of liquidity.
Price Chart
Executive Summary
Ping An Biomedical received a Nasdaq letter on May 26, 2026, granting an additional 180-day compliance period (until November 23, 2026) to regain the $1 minimum bid price. The company remains non-compliant and is evaluating a reverse stock split as a potential cure, but there is no guarantee of success.
Key Facts
- Nasdaq notified the company on November 24, 2025, of bid price non-compliance under Rule 5550(a)(2).
- On May 26, 2026, Nasdaq granted an additional 180-day period until November 23, 2026, to regain compliance.
- The company must maintain a closing bid price of at least $1 for 10 consecutive business days to cure.
- The company intends to use a reverse stock split if necessary, but there is no assurance of regaining compliance.
- Market cap is $19M, indicating a micro-cap with significant delisting risk.
Financial Impact
Delisting risk persists; no financial figures provided in the filing.
Risk Factors
- Failure to regain compliance by November 23, 2026, could result in Nasdaq delisting.
- Reverse stock split may not achieve sustained compliance and could further depress the stock.
- Low market cap ($19M) and ongoing non-compliance signal financial distress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-061559 |
| Document: 0001213900-26-061559-index-headers.html | 0001213900-26-061559 |
| Document: 0001213900-26-061559-index.html | 0001213900-26-061559 |
| Document: 0001213900-26-061559.txt | 0001213900-26-061559 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 22, 2026 3d ago | 6-K | $0.0980 | awaiting T+20 | — | $3.96 (−3940.82%) |
Oct 22, 2026 3d ago | Press Release | $0.1340 | awaiting T+20 | — | $3.96 (+2855.22%) |
Oct 21, 2026 5d ago | 6-K | $3.68 | awaiting T+20 | — | $3.96 (+7.61%) |
Sep 11, 2026 6w ago | 6-K | $0.1380 $0.1220 | ▲ +11.59% | ▲ +13.46% | $3.96 (−2769.57%) |
Jul 20, 2026 14w ago | 6-K | $0.1459 $0.1340 | ▼ −8.16% | ▼ −12.28% | $3.96 (+2614.19%) |
May 27, 2026 21w ago | 6-K | $0.1560 $0.1590 | ▼ −1.92% | ▼ −5.07% | $3.96 (−2438.46%) |
Feb 27, 2026 34w ago | EFFECT | $0.1490 $0.1330 | ▼ −10.74% | ▼ −3.18% | $3.96 (+2557.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers